Forte Biosciences, Inc.

Analysis for Ticker: FBRX

Forte Biosciences, Inc (FBRX) is a clinical-stage biopharmaceutical company that develops biological therapies for autoimmune diseases, chasing clinical trials for a single drug candidate called FB102. The reality is that the company produces zero dollars in commercial revenue and exists as a machine designed to consume shareholder capital. Since its inception, the enterprise has burned through a massive 223,4$ million more than it has ever collected. Think of this company like a builder who keeps selling more and more tickets for a house that has not even been designed yet. Every time they print a new ticket, the piece of the house you thought you owned gets smaller, but the builder still uses your money to pay for his own lunch and his friends at the bank.